Merck Sharp and Dohme Corp. http://www.alacrastore.com/company-snapshot/Merck_Sharp_and_Dohme_Corp-1010916 26 Nov 2009 02:49:01 EST 1010916 Merck Sharp and Dohme Corp. en AlacraStore RSS Builder 1.0 30 US - In ## November ####, the board of Merck & Co. Inc, a New Jersey-based manufacturer and developer of pharmaceutical products, authorized the repurchase of up to USD # bil of the company's common stock outstanding in open market transactions25 Nov 2009 08:29:09 EST589331589331589331589331Merck & Co IncMerck & Co IncMerck & Co IncMerck & Co Inchttp://www.alacrastore.com/storecontent/Thomson_M%26A/Merck_Co_Inc_intends_a_stock_buyback-2130997020sdc/21309970202130997020Copyright © 2009, Thomson Financial, All Rights ReservedNew YorkDrugsUnited StatesPharmaceutical preparations2834NJNew JerseyPublicMRK2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances5122:Drugs, drug proprietaries, and druggists' sundries8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances5122:Drugs, drug proprietaries, and druggists' sundries8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizationsNew YorkDrugsUnited StatesPharmaceutical preparations2834NJNew JerseyPublicMRK10714001Mnfr,dvlp pharmMnfr,dvlp pharmCashCash OnlyCommon Stock10714001Nov 25 20090.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.0000020.0000021.0000022.0000023.0000024.0000025.0000026.0000027.0000028.0000029.0000030.0000031.0000032.0000033.0000034.0000035.0000036.0000037.00000Merck & Co Inc, located inWhitehouse Station, NewJersey, manufactures anddevelops pharmaceuticalproducts such as vaccines andmedicines for the treatment ofhigh blood pressure, elevatedcholesterol levels,osteoporosis, asthma, benignprostatic hyperplasia,arthritis, migraine, glaucoma,emesis, infectious diseases(antibacterial, antifungal,and antiviral agents), andvaccines to prevent childhooddiseases and hepatitis A andB. The products of the groupare sold and distributed todrug wholesalers andretailers, hospitals, clinics,government agencies and healthcare providers such as healthmaintenance organizations andother institutions. Thecompany's branded productsportfolio includes Arcoxia,Ccancidas, Comvax, Cosopt,Cozaar, Crixivan, Emend,Fosamax, Hyzaar, Invanz,Maxalt, Pedvaxhib, Primaxin,Propecia, Proscar, Recombivaxhb, Singulair, Timoptic-xe ,Trusopt, Vioxx and Zocor. Thegroup has operations in theUS, Europe, Middle East,Africa and Japan. The Companywas established in 1891.Merck & Co Inc, located in Whitehouse Station, New Jersey,manufactures and develops pharmaceutical products such asvaccines and medicines for the treatment of high bloodpressure, elevated cholesterol levels, osteoporosis, asthma,benign prostatic hyperplasia, arthritis, migraine, glaucoma,emesis, infectious diseases (antibacterial, antifungal, andantiviral agents), and vaccines to prevent childhooddiseases and hepatitis A and B. The products of the groupare sold and distributed to drug wholesalers and retailers,hospitals, clinics, government agencies and health careproviders such as health maintenance organizations and otherinstitutions. The company's branded products portfolioincludes Arcoxia, Ccancidas, Comvax, Cosopt, Cozaar,Crixivan, Emend, Fosamax, Hyzaar, Invanz, Maxalt, Pedvaxhib,Primaxin, Propecia, Proscar, Recombivax hb, Singulair,Timoptic-xe , Trusopt, Vioxx and Zocor. The group hasoperations in the US, Europe, Middle East, Africa and Japan.The Company was established in 1891.Merck & Co Inc, located in Whitehouse Station, New Jersey, manufactures and develops pharmaceutical products such as vaccines and medicines for the treatment of high blood pressure, elevated cholesterol levels, osteoporosis, asthma, benign prostatic hyperplasia, arthritis, migraine, glaucoma, emesis, infectious diseases (antibacterial, antifungal, and antiviral agents), and vaccines to prevent childhood diseases and hepatitis A and B. The products of the group are sold and distributed to drug wholesalers and retailers, hospitals, clinics, government agencies and health care providers such as health maintenance organizations and other institutions. The company's branded products portfolio includes Arcoxia, Ccancidas, Comvax, Cosopt, Cozaar, Crixivan, Emend, Fosamax, Hyzaar, Invanz, Maxalt, Pedvaxhib, Primaxin, Propecia, Proscar, Recombivax hb, Singulair, Timoptic-xe , Trusopt, Vioxx and Zocor. The group has operations in the US, Europe, Middle East, Africa and Japan. The Company was established in 1891.1.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.0000020.0000021.0000022.0000023.0000024.0000025.0000026.0000027.0000028.0000029.0000030.0000031.0000032.0000033.0000034.0000035.0000036.0000037.00000Merck & Co Inc, located inWhitehouse Station, NewJersey, manufactures anddevelops pharmaceuticalproducts such as vaccines andmedicines for the treatment ofhigh blood pressure, elevatedcholesterol levels,osteoporosis, asthma, benignprostatic hyperplasia,arthritis, migraine, glaucoma,emesis, infectious diseases(antibacterial, antifungal,and antiviral agents), andvaccines to prevent childhooddiseases and hepatitis A andB. The products of the groupare sold and distributed todrug wholesalers andretailers, hospitals, clinics,government agencies and healthcare providers such as healthmaintenance organizations andother institutions. Thecompany's branded productsportfolio includes Arcoxia,Ccancidas, Comvax, Cosopt,Cozaar, Crixivan, Emend,Fosamax, Hyzaar, Invanz,Maxalt, Pedvaxhib, Primaxin,Propecia, Proscar, Recombivaxhb, Singulair, Timoptic-xe ,Trusopt, Vioxx and Zocor. Thegroup has operations in theUS, Europe, Middle East,Africa and Japan. The Companywas established in 1891.Merck & Co Inc, located in Whitehouse Station, New Jersey,manufactures and develops pharmaceutical products such asvaccines and medicines for the treatment of high bloodpressure, elevated cholesterol levels, osteoporosis, asthma,benign prostatic hyperplasia, arthritis, migraine, glaucoma,emesis, infectious diseases (antibacterial, antifungal, andantiviral agents), and vaccines to prevent childhooddiseases and hepatitis A and B. The products of the groupare sold and distributed to drug wholesalers and retailers,hospitals, clinics, government agencies and health careproviders such as health maintenance organizations and otherinstitutions. The company's branded products portfolioincludes Arcoxia, Ccancidas, Comvax, Cosopt, Cozaar,Crixivan, Emend, Fosamax, Hyzaar, Invanz, Maxalt, Pedvaxhib,Primaxin, Propecia, Proscar, Recombivax hb, Singulair,Timoptic-xe , Trusopt, Vioxx and Zocor. The group hasoperations in the US, Europe, Middle East, Africa and Japan.The Company was established in 1891.Merck & Co Inc, located in Whitehouse Station, New Jersey, manufactures and develops pharmaceutical products such as vaccines and medicines for the treatment of high blood pressure, elevated cholesterol levels, osteoporosis, asthma, benign prostatic hyperplasia, arthritis, migraine, glaucoma, emesis, infectious diseases (antibacterial, antifungal, and antiviral agents), and vaccines to prevent childhood diseases and hepatitis A and B. The products of the group are sold and distributed to drug wholesalers and retailers, hospitals, clinics, government agencies and health care providers such as health maintenance organizations and other institutions. The company's branded products portfolio includes Arcoxia, Ccancidas, Comvax, Cosopt, Cozaar, Crixivan, Emend, Fosamax, Hyzaar, Invanz, Maxalt, Pedvaxhib, Primaxin, Propecia, Proscar, Recombivax hb, Singulair, Timoptic-xe , Trusopt, Vioxx and Zocor. The group has operations in the US, Europe, Middle East, Africa and Japan. The Company was established in 1891.0.000000.000000.000002109.18000NU.S. Dollar24 Nov 09Tue, 24 Nov 2009 00:00:00 ESTDate Announced: 11/24/2009Date Effective:BuybackNot Appl.0.000000.000000.000000.000000.000000.00000Price/Share0.000003000 U.S. Dollar3000.000000.000003000 U.S. Dollar3000.000000.000000.000000.000000.000003000.000003000 U.S. Dollar1.00000N1809.627000.000000.000000.000000.000000.000003000.000003000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.00000US - In 24 November 2009, theboard of Merck & Co. Inc, aNew Jersey-based manufacturerand developer ofpharmaceutical products,authorized the repurchase ofup to USD 3 bil of thecompany's common stockoutstanding in open markettransactionsUS - In 24 November 2009, the board of Merck & Co. Inc, a New Jersey-based manufacturer and developer of pharmaceutical products, authorized the repurchase of up to USD 3 bil of the company's common stock outstanding in open market transactionsUS - In 24 November 2009, the board of Merck & Co. Inc, a New Jersey-based manufacturerand developer of pharmaceutical products, authorized the repurchase of up to USD 3 bil ofthe company's common stock outstanding in open market transactionsUS - In 24 November 2009, the board of Merck & Co. Inc, a New Jersey-based manufacturer and developer of pharmaceutical products, authorized the repurchase of up to USD 3 bil of the company's commonstock outstanding in open market transactionsUS - In 24 November 2009, the board of Merck & Co. Inc, a New Jersey-based manufacturer and developer of pharmaceutical products,authorized the repurchase of up to USD 3 bil of the company's common stock outstanding in open market transactionsIntended0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000Status:Intended-999.00000np0.00000-999.00000np0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000002834:Pharmaceutical preparations2836:Biological products, except diagnostic substances5122:Drugs, drug proprietaries, and druggists' sundries8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations10714001New YorkUnited States2834New JerseyPublicMRK2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances5122:Drugs, drug proprietaries, and druggists' sundries8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations10714001New YorkUnited States2834New JerseyPublicMRK3000.000003000.000003000.000001809.62700Deal InformationTF Mergers & Acquisitionshttp://www.alacrastore.com/storecontent/newstex/BW-0001-39995648BW-0001-39995648newstex/BW-0001-39995648xmlNewstex Inc.2005Idera Pharmaceuticals, Inc. Idera Pharmaceuticals, Inc.Newstex Inc.newstex.comnewstexBW-0001-39995648Business Wire0001Business WireBW1Newstex Inc.Business Wire0700000007005000040000000400200004002006070030000700300107014000070140120701400613000000130100001301000525 Nov 2009 08:17:40 EST180000001802200011/25/2009 Nov. ##, #### (Business Wire) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that Novartis will terminate its research collaboration agreement with the Company, effective as of February ##, ####. “We appreciate the...IDERA PHARMACEUTICALS INCMERCK & CO INCMERCK KGAANOVARTIS AGSUDHIR AGRAWALIDRAMKGAYMRKNVSNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-39979436BW-0001-39979436newstex/BW-0001-39979436xmlNewstex Inc.2005Merck & Co., Inc.Newstex Inc.newstex.comnewstexBW-0001-39979436Business Wire0001Business WireBW1Newstex Inc.Business Wire090000000901500004000000040020000400200604016000040160080401600524 Nov 2009 04:19:37 EST1800000018016000190000001900100011/24/2009 Nov. ##, #### (Business Wire) -- At their meeting today, the Board of Directors of Merck & Co., Inc. declared a quarterly dividend of $#.## per share on the company’s common stock for the first quarter of ####. Payment will be made...MERCK & CO INCMRKNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/MW-0001-39969814MW-0001-39969814newstex/MW-0001-39969814xmlNewstex Inc.2005Copyright (c) 2009, Marketwire. All rights reserved. All the news releases provided by Market Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited.Cutting Edge InformationRESEARCH TRIANGLE PARK, NCNewstex Inc.newstex.comnewstexMW-0001-39969814Marketwire0001MarketwireMW1Newstex Inc.Marketwire040000000401600004016005040020000400200602000000020020000200200607000000070140000701401224 Nov 2009 10:21:44 EST180000001801600011/24/2009 RESEARCH TRIANGLE PARK, NC, Nov. ##, #### (Marketwire delivered by Newstex) -- RESEARCH TRIANGLE PARK, NC -- (Marketwire) -- ##/##/## -- According to pharmaceutical deal makers, the recent round of industry M&A is far from over. In...MERCK & CO INCRICHARD T CLARKMRKNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-39956181BW-0001-39956181newstex/BW-0001-39956181xmlNewstex Inc.2005Merck & Co., Inc.Newstex Inc.newstex.comnewstexBW-0001-39956181Business Wire0001Business WireBW1Newstex Inc.Business Wire070000000700500013000000130070001400000014004000040000000400200004002006040160000401600507014000070140010701401707014012020000000200200002002004020020050200300002003002130010001300100223 Nov 2009 08:19:33 EST180000001801600019000000190010001900200411/23/2009 Nov. ##, #### (Business Wire) -- Merck said today that U.S. District Court Judge John F. Keenan granted summary judgment in Merck's favor in Flemings v. Merck . Flemings is the second of three cases involving FOSAMAX (alendronate sodium)...MERCK & CO INCMRKNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-39939289BW-0001-39939289newstex/BW-0001-39939289xmlNewstex Inc.2005MerckNewstex Inc.newstex.comnewstexBW-0001-39939289Business Wire0001Business WireBW1Newstex Inc.Business Wire020000000200200002002004020020060400000004002000040020060401600004016005040060000400600507000000070140000701401223 Nov 2009 09:25:32 EST180000001801600019000000190010001900104311/23/2009 Nov. ##, #### (Business Wire) -- Merck said today that Travis County, Texas District Court Judge Scott H. Jenkins granted Merck's motion for summary judgment, dismissing all claims in a VIOXX-related lawsuit filed on behalf of the...MERCK & CO INCMRKNewsNewstexhttp://www.alacrastore.com/research/moodys-global-credit-research-Moody_s_assigns_P_1_to_Merck_s_new_CP_program_stable_outlook-PR_190497_663000PR_190497_663000moodys/PR_190497_663000html18 Nov 2009 02:13:01 ESThtmlMerck & Co., Inc.Merck Sharp & Dohme Corp.Merck & Co., Inc.; Merck Sharp & Dohme Corp.663000485250663000150.000017 Nov 2009NewsRating ActionCGlobal Credit Research Rating Action ## NOV #### Rating Action: Merck & Co., Inc. Moody's assigns P-# to Merck's new CP program; stable outlook New $## billion commercial paper program New York, November ##, #### -- Moody's Investors...116131614031404140516231757485250568600008223600010747663000663010808863724UNITED STATESINDUSTRIAL663000Credit & Investment ResearchMoody's Global Credit Researchhttp://www.alacrastore.com/storecontent/newstex/BW-0001-39785129BW-0001-39785129newstex/BW-0001-39785129xmlNewstex Inc.2005MerckNewstex Inc.newstex.comnewstexBW-0001-39785129Business Wire0001Business WireBW1Newstex Inc.Business Wire070000000700500004000000040020000400200604016000040160050700100007001005070140000701400917 Nov 2009 10:22:44 EST1800000018016000190000001900100011/17/2009 Nov. ##, #### (Business Wire) -- In a phase IIb study in ### patients with primary hypercholesterolemia or mixed hyperlipidemia treated with anacetrapib as monotherapy or co-administered with atorvastatin, there were persistent lipid...MERCK & CO INCMRKNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-39783530BW-0001-39783530newstex/BW-0001-39783530xmlNewstex Inc.2005Merck & Co., Inc.Newstex Inc.newstex.comnewstexBW-0001-39783530Business Wire0001Business WireBW1Newstex Inc.Business Wire070000000700500011000000110030001400000014023000140100000400000004002000040020060401600004016005040060000400600513000000130010001300100207014000070140190701401207014009070010000700100517 Nov 2009 09:22:42 EST18000000180160001802300019000000190010001900200411/17/2009 Nov. ##, #### (Business Wire) -- In an investigational study, Merck's medicine COZAAR (losartan potassium tablets) ### mg, administered once daily, significantly reduced the risk of all-cause death or hospitalization due to heart failure...MERCK & CO INCMRKNewsNewstexhttp://www.alacrastore.com/research/s-and-p-credit-research-Merck_Co_Inc_New_4_2_Commercial_Paper_Program_Assigned_A_1_Rating_AA_Corporate_Credit_Rating_Affirmed-757614757614spcred/757614normglobal16 Nov 2009 06:20:00 EST100Ratings ActionThe latest Ratings Action from S&PUnited StatesPharmaceuticalsUnited StatesGlobal IssuersRatings ActionUSA58933158933N58933R58933S58933T58933U58933V58933W35202010 352020 3520 35Merck&Co. Inc.101483USAMRKRATING_ACTIONConsumerCORPFIGLOBISSHealthCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/research/s-and-p-credit-research-Research_Update_Merck_Co_Inc_New_4_2_Commercial_Paper_Program_Rated_A_1_AA_Corporate_Credit_Rating_Affirmed-757615757615spcred/757615normglobalstructured16 Nov 2009 06:20:00 EST175Research UpdateThe latest Research Update from S&PUnited StatesPharmaceuticalsGlobal IssuersStructured FinanceResearch UpdateUSA58933158933N35202010 352020 3520 35Merck&Co. Inc.101483USAMRKRESUPDUSA80660580660A80660B35202010 352020 3520 35Merck Sharpe&Dohme Corp.Schering-Plough Corp.102077479424USASGPABSConsumerCORPFIGLOBISSHealthSTRUC58933W58933V58933U58933T58933S58933RUnited StatesCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/storecontent/newstex/BW-0001-39736211BW-0001-39736211newstex/BW-0001-39736211xmlNewstex Inc.2005Merck & Co., Inc.Newstex Inc.newstex.comnewstexBW-0001-39736211Business Wire0001Business WireBW1Newstex Inc.Business Wire0700000007005000070130001400000014006000040000000400200004002006040160000401600507001000070010050701400007014012070140090701401507003000070030010700300313000000130010001300100215 Nov 2009 07:22:58 EST18000000180230001801600019000000190010001900200411/15/2009 Nov. ##, #### (Business Wire) -- At the American Heart Association meeting today, Merck & Co., Inc. said it is confident in the safety and efficacy profiles of ZETIA ® (ezetimibe) and VYTORIN ® (ezetimibe/simvastatin), and issued the...MERCK & CO INCPETER S KIMMRKNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-39714105BW-0001-39714105newstex/BW-0001-39714105xmlNewstex Inc.2005MerckNewstex Inc.newstex.comnewstexBW-0001-39714105Business Wire0001Business WireBW1Newstex Inc.Business Wire1300000013001000130010021301000013010005070000000701400007014009070140120700100007001005070030000700300107011000070110030400000004002000040020060401600004016005040060000400600514 Nov 2009 12:02:50 EST180000001801600018020000190000001900100011/14/2009 Nov. ##, #### (Business Wire) -- Following the completion of its merger with Schering-Plough, Merck today confirms and underscores its commitment to marketing and developing cardiovascular medicines for a range of cardiovascular disorders....MERCK & CO INCPETER S KIMMRKNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/T2549417T2549417ccbn/T2549417norm12 Nov 2009 05:06:57 EST2549417Final Transcript of MRK presentation, 12-Nov-09 11:00am MTMerck & Co., Inc.106.0000FinalMerck & Co., Inc. at Credit Suisse Healthcare Conference TranscriptMRK11:00am MTTranscript...Catherine Arnold - Credit Suisse - Analyst Hello, everyone. I am happy to have Peter Kellogg here today who has the honor of giving Merck's inaugural investor presentation since the new Merck was formed. The new Merck does have plenty on its plate. Just to name a few aspirations for ####, it has to integrate two large companies, nurture several late-stage pipeline assets, and execute a couple business development deals to assure sound, strategic positioning for the next decade. So now that I have reminded Peter of all of his tasks, I am going to turn it over him to let us know how he and his colleagues will accomplish all of that. Peter Kellogg - Merck - CFO Thank you, Catherine. I am a little hoarse today because I have a cold, but maybe that is a signal that we are working hard which is good. I would like to start today with a quick overview of -- obviously I will start with this forward-looking statement. I will make some forward-looking statements in this presentation of course. All... Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/newstex/BW-0001-39637957BW-0001-39637957newstex/BW-0001-39637957xmlNewstex Inc.2005Zacks.comNewstex Inc.newstex.comnewstexBW-0001-39637957Business Wire0001Business WireBW1Newstex Inc.Business Wire0400000004002000040020060401600004016048040160010401601807000000070140000701401211 Nov 2009 06:16:32 EST1800000018008000180040001802000019000000190010001900200711/11/2009 Nov. ##, #### (Business Wire) -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks...BANK OF AMERICA CORPMERCK & CO INCOSI PHARMACEUTICALS INCPFIZER INCBACMRKOSIPPFENewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-39623401BW-0001-39623401newstex/BW-0001-39623401xmlNewstex Inc.2005OPKO Health, Inc.Newstex Inc.newstex.comnewstexBW-0001-39623401Business Wire0001Business WireBW1Newstex Inc.Business Wire070000000701400007014019070140080700100007001004040000000401600004016005040020000400200611 Nov 2009 09:18:30 EST18000000180160001802000011/11/2009 Nov. ##, #### (Business Wire) -- OPKO Health, Inc. (NYSE Amex:OPK) today announced that it has completed the acquisition of rolapitant and a related compound from Schering Corporation, a subsidiary of Merck & Co., Inc. ("Schering")....MERCK & CO INCOPKO Health, Inc.MRKOPKNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-39586213BW-0001-39586213newstex/BW-0001-39586213xmlNewstex Inc.2005Fero Industries, Inc.Newstex Inc.newstex.comnewstexBW-0001-39586213Business Wire0001Business WireBW1Newstex Inc.Business Wire070000000700100004000000040020000400200604016000040160050701400007014012070030000700300113000000130100001301000510 Nov 2009 10:22:20 EST18000000180160001900000019001000190010211900200411/10/2009 Nov. ##, #### (Business Wire) -- Fero Industries, Inc. (OTCBB: FROI) (the “Company”) is pleased to announce to the appointment of Robert C. Moellering, Jr., M.D. as Chairman of the Scientific Advisory Board of Pyro Pharmaceuticals,...BRISTOL MYERS SQUIBB COBRISTOL-MYERS SQUIBB COMPANY $2 CONVERTIBLEFERO INDUSTRIES INC.MERCK & CO INCBMYBMY PRFROIMRKNewsNewstexhttp://www.alacrastore.com/research/moodys-global-credit-research-Moody_s_affirms_Merck_upgrades_Schering_outlook_now_stable-PR_189693_663000PR_189693_663000moodys/PR_189693_663000html06 Nov 2009 12:39:48 ESThtmlMerck & Co., Inc.Schering-Plough CorporationMerck & Co., Inc.; Schering-Plough Corporation663000485250663000150.000005 Nov 2009NewsRating ActionCGlobal Credit Research Rating Action # NOV #### Rating Action: Schering-Plough Corporation Moody's affirms Merck, upgrades Schering; outlook now stable Approximately $## billion of rated debt and preferred stock affected. New York,...116131614031404140516231757485250568600008223600010747663000663010808863724UNITED STATESINDUSTRIAL485250663000Credit & Investment ResearchMoody's Global Credit Researchhttp://www.alacrastore.com/research/s-and-p-credit-research-Merck_Co_Inc_Gets_Multiple_Rating_Actions_Schering_Plough_Ratings_Raised_Off_Watch-755444755444spcred/755444normglobalstructured05 Nov 2009 04:30:00 EST100Ratings ActionThe latest Ratings Action from S&PUnited StatesPharmaceuticalsUnited StatesRatings ActionUSA58933158933N58933R58933S58933T35202010 352020 3520 35Merck&Co. Inc.101483USAMRKNEWSRATING_ACTIONUSA80660580660A80660B35202010 352020 3520 35Schering-Plough Corp.102077USASGPABSConsumerCORPFIGLOBISSHealthSTRUC58933W58933V58933UStructured FinanceGlobal IssuersCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/research/s-and-p-credit-research-Research_Update_Merck_Co_Inc_Multiple_Rating_Actions_Schering_Plough_Ratings_Raised_Off_Watch-755445755445spcred/755445normglobal05 Nov 2009 04:30:00 EST175Research UpdateThe latest Research Update from S&PPharmaceuticalsUnited StatesGlobal IssuersResearch UpdateUSA58933158933N58933R58933S58933T58933U58933V58933WMerck&Co. Inc.101483USAMRKRESUPDConsumerCORPFIGLOBISSHealth35202010 352020 3520 35United StatesCredit & Investment ResearchS&P Credit Research